clinical trial · NCT06926634

Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)

Washington University School of Medicine →·phase2·recruiting·n = 32

High Grade Neuroendocrine NeoplasmsZanzalintinib

brief summary

The investigators hypothesize that zanzalintinib maintenance therapy after initial cytotoxic chemotherapy can prolong the progression-free survival (PFS) in patients with high-grade NENs.

started

Dec 9, 2025

primary completion

Dec 31, 2034

completion

Dec 31, 2034

last updated

Dec 17, 2025

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol